Institute of Virology Muenster, University of Muenster, Muenster, Germany.
Institute of Hygiene, University Hospital Muenster, University of Muenster, Muenster, Germany.
PLoS Pathog. 2024 Oct 15;20(10):e1012624. doi: 10.1371/journal.ppat.1012624. eCollection 2024 Oct.
Neutralising antibodies against the SARS-CoV-2 spike (S) protein are major determinants of protective immunity, though insufficient antibody responses may cause the emergence of escape mutants. We studied the humoral immune response causing intra-host evolution in a B-cell depleted, haemato-oncologic patient experiencing clinically severe, prolonged SARS-CoV-2 infection with a virus of lineage B.1.177.81. Following bamlanivimab treatment at an early stage of infection, the patient developed a bamlanivimab-resistant mutation, S:S494P. After five weeks of apparent genetic stability, the emergence of additional substitutions and deletions within the N-terminal domain (NTD) and the receptor binding domain (RBD) of S was observed. Notably, the composition and frequency of escape mutations changed in a short period with an unprecedented dynamic. The triple mutant S:Delta141-4 E484K S494P became dominant until virus elimination. Routine serology revealed no evidence of an antibody response in the patient. A detailed analysis of the variant-specific immune response by pseudotyped virus neutralisation test, surrogate virus neutralisation test, and immunoglobulin-capture enzyme immunoassay showed that the onset of an IgM-dominated antibody response coincided with the appearance of escape mutations. The formation of neutralising antibodies against S:Delta141-4 E484K S494P correlated with virus elimination. One year later, the patient experienced clinically mild re-infection with Omicron BA.1.18, which was treated with sotrovimab and resulted in an increase in Omicron-reactive antibodies. In conclusion, the onset of an IgM-dominated endogenous immune response in an immunocompromised patient coincided with the appearance of additional mutations in the NTD and RBD of S in a bamlanivimab-resistant virus. Although virus elimination was ultimately achieved, this humoral immune response escaped detection by routine diagnosis and created a situation temporarily favouring the rapid emergence of various antibody escape mutants with known epidemiological relevance.
中和抗体是针对 SARS-CoV-2 刺突(S)蛋白的主要决定因素,尽管抗体反应不足可能导致逃逸突变的出现。我们研究了在经历临床严重、长期 SARS-CoV-2 感染的 B 细胞耗竭的血液肿瘤患者体内引起宿主内进化的体液免疫反应,该患者感染的病毒属于谱系 B.1.177.81。在感染早期接受巴美替尼治疗后,患者出现了巴美替尼耐药突变 S:S494P。在明显遗传稳定五周后,观察到 S 的 N 端结构域(NTD)和受体结合域(RBD)内出现额外的取代和缺失。值得注意的是,逃逸突变的组成和频率在短时间内发生了前所未有的变化。三重突变 S:Delta141-4 E484K S494P 成为优势突变,直到病毒被清除。常规血清学检测未发现患者存在抗体反应的证据。通过假病毒中和试验、替代病毒中和试验和免疫球蛋白捕获酶免疫分析对变异特异性免疫反应的详细分析表明,IgM 主导的抗体反应的出现与逃逸突变的出现同时发生。针对 S:Delta141-4 E484K S494P 的中和抗体的形成与病毒清除相关。一年后,该患者经历了临床症状轻微的奥密克戎 BA.1.18 再次感染,用索托维单抗进行了治疗,并导致对奥密克戎有反应的抗体增加。总之,在免疫功能低下的患者中,IgM 主导的内源性免疫反应的出现与 NTD 和 RBD 中额外的 S 突变同时发生在对巴美替尼耐药的病毒中。尽管最终实现了病毒清除,但这种体液免疫反应逃避了常规诊断的检测,并暂时创造了有利于各种具有已知流行病学相关性的抗体逃逸突变快速出现的情况。